The Company
An experienced team and an accomplished board
Kynos is led by an experienced team and leverages many years of research on KMO conducted by Kynos founders and their collaborators. With the support of an accomplished board and its stakeholders, Kynos has moved its lead KMO inhibitor rapidly into clinical development.
The company is backed by leading specialist biotech investors and has been awarded non-dilutive funding from Innovate UK supporting the Phase I first-in-human study of its lead KMO inhibitor, KNS366.
Investors
The Leadership team
-
Jonathan Savidge
CEO
-
Damian Mole
CSO AND CO-FOUNDER
-
Scott Webster
CTO AND CO-FOUNDER
-
Alison Strutt
CFO
-
David Brocklebank
DIRECTOR, CLINICAL OPERATIONS
The Board of Directors
-
Jean Combalbert
INDEPENDENT CHAIR
-
Elizabeth Roper
INVESTOR DIRECTOR
-
Craig Richardson
INVESTOR DIRECTOR
-
Jonathan Savidge
CEO
-
Damian Mole
CSO AND CO-FOUNDER